UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035865
Receipt number R000040854
Scientific Title Optimal regimens of glucocorticoids tapering for remission induction therapy in patients with severe systemic lupus erythematosus : multi-center randomized open label trial
Date of disclosure of the study information 2019/02/13
Last modified on 2020/02/19 08:34:34

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Optimal regimens of glucocorticoids tapering for remission induction therapy in patients with severe systemic lupus erythematosus : multi-center randomized open label trial

Acronym

Optimal regimens of glucocorticoids tapering in patients with systemic lupus erythematosus

Scientific Title

Optimal regimens of glucocorticoids tapering for remission induction therapy in patients with severe systemic lupus erythematosus : multi-center randomized open label trial

Scientific Title:Acronym

Optimal regimens of glucocorticoids tapering in patients with systemic lupus erythematosus

Region

Japan


Condition

Condition

systemic lupus erythematosus

Classification by specialty

Clinical immunology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In patients with severe SLE, noninferiority is examined by comparing the relapse-free survival rate of the corticosteroid rapidly decreasing group and the conventional therapy group.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Relapse free survival rate at week 52.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Dose comparison

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Dose of glucocorticoids.

Rapid tapering group
After continuing the initial dose for 2 to 4 weeks, weigh down every 1 week according to the following dose
60 mg, 50 mg, 45 mg, 40 mg, 35 mg, 30 mg,
(Tapering every week, continuation of hospitalization, subsequent doses are exclusive to outpatient physician)

Interventions/Control_2

Conventional therapy group
Initial dose is continued for 2 to 4 weeks and then reduced every 2 weeks according to the following dose
60 mg, 50 mg, 45 mg, 40 mg, (Tapering every 2 weeks, be sure to continue hospitalization)
37.5 mg, 35 mg, 32.5 mg, 30 mg, (Tapering every 4 weeks, subsequent doses are exclusive to outpatient physician)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients over 20 years old
2) Patients who got consent in writing
3) Patients who met SLE classification criteria or SLICC classification criteria of the American College of Rheumatology 1997 and were diagnosed with SLE in 1997
4) In principle, a combination of immunosuppressive drugs receiving medicine of corticosteroid at a dose of 0.5 mg / kg / day or more and 40 mg / day in terms of prednisolone is used but patients with or without interruption due to side effects etc.

Key exclusion criteria

1) Persons who did not obtain consent
2) Patients with poorly controlled complications
3) Pregnant or lactating women
4) Male and female with pregnancy plan within 52 weeks

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Naoto
Middle name
Last name Tamura

Organization

Juntendo University

Division name

Department of Internal Medicine and Rheumatology

Zip code

1130033

Address

2-1-1, Hongo, Bunkyo-Ku, Tokyo, Japan

TEL

03-3813-3111

Email

tnaoto@juntendo.ac.jp


Public contact

Name of contact person

1st name Yoshiyuki
Middle name
Last name Abe

Organization

Juntendo University

Division name

Department of Internal Medicine and Rheumatology

Zip code

1130033

Address

2-1-1, Hongo, Bunkyo-Ku, Tokyo, Japan

TEL

03-3813-3111

Homepage URL


Email

yo-abe@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Juntendo University

Address

2-1-1, Hongo, Bunkyo-Ku, Tokyo

Tel

0338133111

Email

kenkyu5858@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 02 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

44

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2019 Year 01 Month 07 Day

Date of IRB

2019 Year 01 Month 09 Day

Anticipated trial start date

2019 Year 02 Month 13 Day

Last follow-up date

2024 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Transition to jRCT.(jRCT1031180196)


Management information

Registered date

2019 Year 02 Month 13 Day

Last modified on

2020 Year 02 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040854


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name